Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
News|Articles|September 4, 2026
AI's Evolving Role in Radiation Oncology
Author(s)Cancer Network Staff
How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.
Advertisement
Advertisement
Artificial intelligence (AI) has arrived in oncology not as a distant forecast but as a daily reality, shaping how notes are written, how tumor boards prepare, how treatment plans are optimized, and how patients navigate a system that was already formidably complex before algorithms entered the examination room. The question facing clinicians is no longer whether AI belongs in cancer care but how to deploy it rigorously, equitably, and without losing the irreplaceable human core of medicine.
Related to this article
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement